Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Supernus Pharmaceuticals Inc (SUPN)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Supernus's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
28.87 -0.13    -0.45%
18/04 - Closed. Currency in USD ( Disclaimer )
After Hours
28.87
-0.00
-0.00%
16:20:00 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 328,084
  • Bid/Ask: 18.44 / 40.00
  • Day's Range: 28.72 - 29.48
Supernus 28.87 -0.13 -0.45%

NASDAQ:SUPN Financials

 
A brief overview of the NASDAQ:SUPN financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of Supernus over time.

Supernus Pharmaceuticals, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was USD 607.52 million compared to USD 667.24 million a year ago. Net income was USD 1.32 million compared to USD 60.71 million a year ago. Basic earnings per share from continuing operations was USD 0.02 compared to USD 1.13 a year ago. Diluted earnings per share from continuing operations was USD 0.02 compared to USD 1.04 a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

SUPN Income Statement

Gross margin TTM 86.21%
Operating margin TTM 2.21%
Net Profit margin TTM 0.22%
Return on Investment TTM 0.94%
 Total Revenue  Net Income
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Revenue 164.31 153.88 135.56 153.76
Gross Profit 144.69 134.28 114.47 130.3
Operating Income 18.99 7.68 -16.8 3.53
Net Income 1.18 -15.98 -0.831 16.95

SUPN Balance Sheet

Quick Ratio MRQ 1.38
Current Ratio MRQ 1.7
LT Debt to Equity MRQ -
Total Debt to Equity MRQ 4.51%
 Total Assets  Total Liabilities
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Assets 1277.67 1285.16 1293.1 1791.81
Total Liabilities 356.16 372.97 373.19 879.66
Total Equity 921.52 912.19 919.91 912.15

SUPN Cash Flow Statement

Cash Flow/Share TTM 2.03
Revenue/Share TTM 11.12
Operating Cash Flow  15.49%
 Cash  Net Change in Cash
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities 44.96 35.88 -18.87 49.13
Cash From Investing Activities -65.98 34.63 60.3 239.78
Cash From Financing Activities 1.09 -0.23 -478.92 80.17
Net Change in Cash -19.93 70.28 -437.49 369.08
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

SUPN Comments

Write your thoughts about Supernus Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
John Moris
John Moris Mar 02, 2021 1:02PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
good fundamentals, discount price, solid company. Nice price to add @ 25,20?
Reply
3 0
Report
Josef Kurzmann
Josef Kurzmann Mar 02, 2021 1:02PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
I'm waiting for $20 and maybe $15.
Reply
0 0
Report
Josef Kurzmann
Josef Kurzmann Mar 02, 2021 1:02PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
the last earnings report was not good so that should put pressure on the stock price for now (at least until the next earnings report).
Reply
0 0
Report
John Moris
John Moris Mar 02, 2021 1:02PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Josef Kurzmann what do you find it was not good in the last report?
Reply
0 0
Report
Josef Kurzmann
Josef Kurzmann Mar 02, 2021 1:02PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
declining earnings and revenues compared to the prior quarter.
Reply
0 0
Report
Josef Kurzmann
Josef Kurzmann Mar 02, 2021 1:02PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
i know if the earnings and revenues decline for 1 quarter it isn't a big thing but what will happen if they decline for 2 or 3 quarters, we would possible see $15
Reply
0 0
Report
Josef Kurzmann
Josef Kurzmann Feb 23, 2021 9:52AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
i sold a couple of days ago, seems like the real market crash is finally coming. I'll re-visit SUPN in a couple of months and decide if the share price fell deep enough.
Reply
1 3
Report
Josef Kurzmann
Josef Kurzmann Feb 09, 2021 8:58AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
yesterday i sent this stock as an "tip" to some stock advisors and hedge funds (only about 5 combined). the price rose 4.38% and today it is up 3.39% in the pre-market. i will tell more fund managers about this stock and then the price should jump really quick.
Reply
2 3
Report
David Bieleski
David Bieleski Feb 09, 2021 8:58AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
That moment when Josef thinks he is moving markets
Reply
0 1
Report
Josef Kurzmann
Josef Kurzmann Jan 30, 2021 3:00PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
one more time:I don't have the knowledge to make an educated guess if the FDA will or will not approve the new ADHD treatment and i am pretty sure you don't have the knowledge and insight eigther.What i know if that SUPN had a great balance sheet, is growing it's revenues 30% per year/earnings 40% per year both since 2016. I also know that their P/E ratio is at 12.5. so i can tell you, even if the new drug doesn't get approved the stock should be at around $90 per share (4.5 billion market cap). Right now it is at $30. If the new drug gets approved it should easily be at $100+ by the end of next year (December 2022) that is a 200%+ return in 23 months.
Reply
3 1
Report
Hyborian War
HyborianWar Jan 30, 2021 3:00PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
BBRW
Reply
0 1
Report
Josef Kurzmann
Josef Kurzmann Jan 29, 2021 8:33AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
supernus has a great risk/reward ratio. since 2016 earnings and revenues more than doubled yet the stock price is down 50% ($30 as I'm writing) . revenues and earnings are growing very fast (30%/40%p.a.) and this all makes it very likely that this stock quadrouples over the next 3-5 years.
Reply
2 1
Report
Josef Kurzmann
Josef Kurzmann Jan 29, 2021 8:33AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
and i didn't even factor in that they have a new revolutionary treatment for ADHD in trial 3 that could be approved by the FDA (then the stock would be worth even more).
Reply
1 1
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email